Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos brasileiros de oftalmologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492019000500381 |
Resumo: | ABSTRACT Purpose: To evaluate the effectiveness in intraocular pressure reduction and safety of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma. Methods: We prospectively evaluated a case series of 21 eyes of 21 consecutive patients with refractory glaucoma treated with micropulse transscleral diode cyclophotocoagulation at 12-month follow-up. The total treatment time was at the discretion of the surgeon, considering baseline and target intraocular pressure and glaucoma diagnosis. Intraocular pressure, inflammation, visual acuity, and number of medications were monitored. Success was defined as intraocular pressure between 6 and 21 mmHg and/or 30% reduction from baseline intraocular pressure with or without the use of antiglaucoma medications. Visual acuity loss was defined as a loss of ≥2 lines of vision on the Snellen chart or a ≥2-level decrease in visual function in patients with nonmeasurable chart acuity. Results: The mean age was 61.04 ± 12.99 years, and 11 (52.4%) patients were male, with most (95%) patients showing low visual acuity at baseline (count fingers or worse). The mean intraocular pressure was 33.38 ± 15.95 mmHg, and the mean number of medications was 3.5 ± 1.1 at baseline. After 1, 3, 6, and 12 months, 76.19%, 57.14%, 55.56%, and 66.67%, respectively, of the patients were classified as treatment successes. Seven (33.3%) patients required new laser treatment and were considered treatment failures. The mean intraocular pressure reduction was 44.72% ± 29.72% in the first week and 41.59% ± 18.93% at the end of follow-up (p=0.006). The mean number of medications significantly dropped to 2.00 ± 1.7 at the 12-month visit (p=0.044). Complications included hypotony (4.8%), intraocular inflammation after 1 month (19%), and visual acuity loss (4.8%). Conclusions: Micropulse transscleral diode cyclophotocoagulation was safe and effective for reducing intraocular pressure in eyes with refractory and advanced glaucoma, with reduced need for ocular antihypertensive medication. |
id |
CBO-2_cdaf678857c35ce6443d8c42b1c3422f |
---|---|
oai_identifier_str |
oai:scielo:S0004-27492019000500381 |
network_acronym_str |
CBO-2 |
network_name_str |
Arquivos brasileiros de oftalmologia (Online) |
repository_id_str |
|
spelling |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year resultsGlaucomaLaser therapyMicropulse transscleral diode cyclophotocoagulationIntraocular pressureLaser, semiconductorABSTRACT Purpose: To evaluate the effectiveness in intraocular pressure reduction and safety of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma. Methods: We prospectively evaluated a case series of 21 eyes of 21 consecutive patients with refractory glaucoma treated with micropulse transscleral diode cyclophotocoagulation at 12-month follow-up. The total treatment time was at the discretion of the surgeon, considering baseline and target intraocular pressure and glaucoma diagnosis. Intraocular pressure, inflammation, visual acuity, and number of medications were monitored. Success was defined as intraocular pressure between 6 and 21 mmHg and/or 30% reduction from baseline intraocular pressure with or without the use of antiglaucoma medications. Visual acuity loss was defined as a loss of ≥2 lines of vision on the Snellen chart or a ≥2-level decrease in visual function in patients with nonmeasurable chart acuity. Results: The mean age was 61.04 ± 12.99 years, and 11 (52.4%) patients were male, with most (95%) patients showing low visual acuity at baseline (count fingers or worse). The mean intraocular pressure was 33.38 ± 15.95 mmHg, and the mean number of medications was 3.5 ± 1.1 at baseline. After 1, 3, 6, and 12 months, 76.19%, 57.14%, 55.56%, and 66.67%, respectively, of the patients were classified as treatment successes. Seven (33.3%) patients required new laser treatment and were considered treatment failures. The mean intraocular pressure reduction was 44.72% ± 29.72% in the first week and 41.59% ± 18.93% at the end of follow-up (p=0.006). The mean number of medications significantly dropped to 2.00 ± 1.7 at the 12-month visit (p=0.044). Complications included hypotony (4.8%), intraocular inflammation after 1 month (19%), and visual acuity loss (4.8%). Conclusions: Micropulse transscleral diode cyclophotocoagulation was safe and effective for reducing intraocular pressure in eyes with refractory and advanced glaucoma, with reduced need for ocular antihypertensive medication.Conselho Brasileiro de Oftalmologia2019-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492019000500381Arquivos Brasileiros de Oftalmologia v.82 n.5 2019reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20190076info:eu-repo/semantics/openAccessJammal,Alessandro AdadCosta,Danilo CamposVasconcellos,José Paulo CabralCosta,Vital Paulinoeng2019-09-05T00:00:00Zoai:scielo:S0004-27492019000500381Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2019-09-05T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false |
dc.title.none.fl_str_mv |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
title |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
spellingShingle |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results Jammal,Alessandro Adad Glaucoma Laser therapy Micropulse transscleral diode cyclophotocoagulation Intraocular pressure Laser, semiconductor |
title_short |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
title_full |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
title_fullStr |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
title_full_unstemmed |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
title_sort |
Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results |
author |
Jammal,Alessandro Adad |
author_facet |
Jammal,Alessandro Adad Costa,Danilo Campos Vasconcellos,José Paulo Cabral Costa,Vital Paulino |
author_role |
author |
author2 |
Costa,Danilo Campos Vasconcellos,José Paulo Cabral Costa,Vital Paulino |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Jammal,Alessandro Adad Costa,Danilo Campos Vasconcellos,José Paulo Cabral Costa,Vital Paulino |
dc.subject.por.fl_str_mv |
Glaucoma Laser therapy Micropulse transscleral diode cyclophotocoagulation Intraocular pressure Laser, semiconductor |
topic |
Glaucoma Laser therapy Micropulse transscleral diode cyclophotocoagulation Intraocular pressure Laser, semiconductor |
description |
ABSTRACT Purpose: To evaluate the effectiveness in intraocular pressure reduction and safety of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma. Methods: We prospectively evaluated a case series of 21 eyes of 21 consecutive patients with refractory glaucoma treated with micropulse transscleral diode cyclophotocoagulation at 12-month follow-up. The total treatment time was at the discretion of the surgeon, considering baseline and target intraocular pressure and glaucoma diagnosis. Intraocular pressure, inflammation, visual acuity, and number of medications were monitored. Success was defined as intraocular pressure between 6 and 21 mmHg and/or 30% reduction from baseline intraocular pressure with or without the use of antiglaucoma medications. Visual acuity loss was defined as a loss of ≥2 lines of vision on the Snellen chart or a ≥2-level decrease in visual function in patients with nonmeasurable chart acuity. Results: The mean age was 61.04 ± 12.99 years, and 11 (52.4%) patients were male, with most (95%) patients showing low visual acuity at baseline (count fingers or worse). The mean intraocular pressure was 33.38 ± 15.95 mmHg, and the mean number of medications was 3.5 ± 1.1 at baseline. After 1, 3, 6, and 12 months, 76.19%, 57.14%, 55.56%, and 66.67%, respectively, of the patients were classified as treatment successes. Seven (33.3%) patients required new laser treatment and were considered treatment failures. The mean intraocular pressure reduction was 44.72% ± 29.72% in the first week and 41.59% ± 18.93% at the end of follow-up (p=0.006). The mean number of medications significantly dropped to 2.00 ± 1.7 at the 12-month visit (p=0.044). Complications included hypotony (4.8%), intraocular inflammation after 1 month (19%), and visual acuity loss (4.8%). Conclusions: Micropulse transscleral diode cyclophotocoagulation was safe and effective for reducing intraocular pressure in eyes with refractory and advanced glaucoma, with reduced need for ocular antihypertensive medication. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492019000500381 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492019000500381 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/0004-2749.20190076 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Oftalmologia v.82 n.5 2019 reponame:Arquivos brasileiros de oftalmologia (Online) instname:Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
instname_str |
Conselho Brasileiro de Oftalmologia (CBO) |
instacron_str |
CBO |
institution |
CBO |
reponame_str |
Arquivos brasileiros de oftalmologia (Online) |
collection |
Arquivos brasileiros de oftalmologia (Online) |
repository.name.fl_str_mv |
Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO) |
repository.mail.fl_str_mv |
aboonline@cbo.com.br||abo@cbo.com.br |
_version_ |
1754209030391201792 |